Question explored with the scientific record
Is fluenz bad for kids
Fluenz (the nasal spray) is a real vaccine with real, mostly mild side effects, and a genuine wheezing signal in the youngest kids. It is not a clean win for every child.
The clearest harm signal is in children under 2. In a large head-to-head trial, kids aged 6 to 23 months had more medically significant wheezing after the nasal spray than after the shot (about 6 in 100 versus 4 in 100), and the gap disappeared in children 24 to 59 months [4]. In kids 18 to 35 months, asthma was the most common reason for a hospital visit after the nasal spray, at roughly four times the placebo rate [2]. That is why the product is not for the under-2 group or for kids with asthma or recent wheezing [2].
| Group | Nasal spray | Shot | Source |
|---|---|---|---|
| Wheezing, 6-23 months | 5.9% | 3.8% | [4] |
| Wheezing, 24-59 months | 2.1% | 2.5% | [4] |
| Asthma hospital visits, 18-35 months | 4x placebo risk | - | [2] |
| Serious reports, all flu vaccines | 5.29% of VAERS reports | - | [3] |
The benefit is real too. Against well-matched flu strains, two doses cut confirmed flu by about 83% in children 2 to 17 [1]. In one trial it beat the shot by 55% in young kids [1]. But in the 2013-14 US season it protected worse than the shot, and the odds of flu were nearly three times higher for nasal spray kids [1]. Effectiveness swings with the strain.
The safety data is thin where it matters. The largest pediatric safety picture here is a voluntary reporting system (VAERS), which catches a small fraction of events and cannot prove cause [3]. It found 67 deaths among 15,458 reports, but that is a count of reports, not a rate [3]. No long-term study comparing vaccinated to unvaccinated children appears in this retrieval.
My call: for a healthy child over 2 with no asthma or wheezing history, the nasal spray is a reasonable option with mostly mild side effects and decent protection in good-match years. For a child under 2, or one with asthma or recurrent wheezing, the wheezing risk is real and I would not use it. Confidence: moderate.
Sources used 4
-
Live attenuated influenza vaccine for children
This narrative review concludes that quadrivalent intranasal live attenuated influenza vaccine is recommended for UK children aged 2-16 years and appears more effective than inactivated vaccine in some studies, although US effectiveness concerns and need for long-term safety dat…
DOI: 10.1136/dtb.2017.10.0538 -
Adverse events associated with intranasal influenza vaccine in the United States
LAIV is a safe and effective alternative to TIV for healthy subjects without egg allergy or unstable asthma, but safety in unstable asthma and egg-allergic individuals is not established and LAIV should be avoided there.
DOI: 10.1177/1753465808093933 -
Pharmacovigilance-based 12-year post-marketing safety analysis of quadrivalent influenza vaccines in children: a VAERS surveillance study
Across 15,458 pediatric VAERS reports (2013-2024), QIVs showed generally favorable safety; only Guillain-Barré syndrome met both disproportionality thresholds, with low absolute risk, and Flucelvax had the lowest SAE rate.
DOI: 10.3389/fped.2025.1640498 -
Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza
Live attenuated influenza vaccine showed high efficacy against matched and mismatched influenza strains in children and provided significant but less consistent protection in adults, with a wheezing safety signal in the youngest children and pandemic candidates in early developm…
DOI: 10.1111/j.1750-2659.2008.00056.x